Skip to main content

Table 1 GDC-0449 lowers the IC-50 of erlotinib/cisplatin in A549M / H1299 cells

From: Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs

Cell Line

Standard Therapy

IC50 (μM)

% Decrease in IC50

Without GDC

With GDC

A549

Erlotinib

11.56

11.27

2.51

Cisplatin

4.11

4.04

1.70

A549M

Erlotinib

43.64

15.76

63.89

Cisplatin

36.16

9.64

73.34

H1299

Erlotinib

10.57

7.20

31.90

Cisplatin

12.15

4.19

65.56

  1. Cells were pre-treated with 20nM GDC-0449 (GDC) for 72 h or vehicle control, prior to treatments with increasing doses of erlotinib or cisplatin for 72 h.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us